“Game Changer for patients with no life lengthening treatment options.”
NICE draft guidance recommends new treatment for chronic heart failure.
People with a certain type of heart failure called Heart Failure with Preserved Ejection Fraction (HFpEF), meaning the heart doesn’t fill properly and Heart Failure with mildly reduced Ejection Fraction (HFmrEF) which means the heart doesn’t pump out blood efficiently, have now got a life lengthening treatment recommended by NICE.
NICE (National Institute for Health and Care Excellence) has today – 18th May 2023 issued final draft guidance which recommends Dapagliflozin (Forxiga, made by AstraZeneca) as an option for adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction.
This is the first treatment that modifies the disease trajectory of these two patient populations. Dapagliflozin is the first NICE-recommended treatment for this population. This treatment not only helps people live longer, with a better quality of life, but also reduces their risk of being admitted to hospital with worsening heart failure.
Previously, Dapagliflozin was recommended to treat people with another type of heart failure called Heart Failure with Reduced Ejection Fraction (HFrEF). We now have a treatment that is recommended for all types of heart failure.
With approximately 1 million people living with heart failure and 50% of those with HFpEF this is a moment of change for how we help those people live better with heart failure.
Read the full NICE press release here.
Read the AstraZeneca UK press release here.